Handelsavisen
prelaunch
Companies Healthcare 4883.T
48
4883.T Tokyo Stock Exchange Biotechnology & Medical Research

4883.T

¥35,00
Open in Charts → Attach watcher ⌖
JPY
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
P/E
EV / Rev
Div yield
0,00 %
Op margin
ROE
-77,1 %
Net margin
Debt / equity
0,00
Beta
52w range
Volume
Day range
Prev close
Open
Next earnings
Ex-dividend
TR 1Y
About

The company operates in the biotechnology and medical research sector, focusing on pharmaceuticals and medical research, and generates revenue primarily through the development and commercialization of biotechnology products.

Business. The company operates in the biotechnology and medical research sector, focusing on pharmaceuticals and medical research, and generates revenue primarily through the development and commercialization of biotechnology products.

Classification92 %
SectorHealthcare
Business sectorPharmaceuticals & Medical Research
IndustryBiotechnology & Medical Research
ActivityPharmaceuticals & Medical Research
Generated · model-assisted
Sell-side consensus
consensus pending
— buy— hold— sell
Avg 12m price target
Upcoming events
— missing data
See all catalysts →

At a glance

Score
not yet scored
Valuation
valuation pending
Analysts
not yet wired
Ownership
not yet wired
Profitability
-77,1 %
return on equity
Quality
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning 4883.
  • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to 4883.T. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    The company operates in the biotechnology and medical research sector, focusing on pharmaceuticals and medical research, and generates revenue primarily through the development and commercialization of biotechnology products.

    Classification92 %
    SectorHealthcare
    Business sectorPharmaceuticals & Medical Research
    IndustryBiotechnology & Medical Research
    ActivityPharmaceuticals & Medical Research
    AI synthesis
    GENERATED

    The company maintains a strong liquidity position, with cash and equivalents amounting to ¥2.81 billion, significantly exceeding its total liabilities of ¥170.95 million, resulting in a current ratio of 21.46. The absence of long-term debt and a debt-to-equity ratio of 0.0 further underscore its robust capital structure. However, the company reported negative returns on equity and assets of -7.71% and -7.26%, respectively, indicating poor profitability and returns relative to its equity and asset base.

    The company's financial performance is marked by a net loss of ¥2.15 billion and an operating loss of ¥2.21 billion, with no revenue reported in the latest period. These figures suggest a challenging operating environment and a lack of revenue generation, which is a concern given the industry's preference for metrics such as revenue growth and operating margins. The company's performance is significantly below the industry median for profitability and returns, highlighting a need for strategic improvements in its operations and revenue streams.

    The company's revenue concentration is not disclosed in the available data, but the absence of revenue in the latest period suggests a potential over-reliance on a few products or markets, which could pose a risk to its financial stability. The lack of revenue also indicates a possible disruption in its business model or market conditions affecting its ability to generate income.

    The company's growth trajectory is currently negative, with a net loss and no revenue reported. The absence of revenue and the significant operating loss suggest a decline in business performance, which could impact its future growth prospects. The company's capital expenditure of ¥2.57 million indicates minimal investment in new projects or expansion, which may limit its ability to drive future revenue growth.

    The company's risk assessment indicates low liquidity and dilution risks, with no immediate filing-based liquidity or dilution flags detected. The absence of long-term debt and a strong cash position further support the low liquidity risk. However, the company's poor profitability and lack of revenue could pose long-term risks to its financial stability.

    Recent financial filings and transcripts do not provide additional insights into the company's operations or strategic direction. The lack of revenue and the significant net loss suggest potential challenges in the company's business model or market conditions that require further investigation.

    Key takeaways
    • The company has a strong liquidity position with a current ratio of 21.46 and no long-term debt.
    • The company reported a net loss of ¥2.15 billion and an operating loss of ¥2.21 billion, with no revenue in the latest period.
    • The company's return on equity and assets are negative, indicating poor profitability and returns.
    • The company's growth trajectory is negative, with no revenue and a significant operating loss.
    • The company's risk assessment indicates low liquidity and dilution risks, but its financial performance is a concern.
    • "margin_outlook_rationale": "The company's operating margin is negative, indicating poor cost control and pricing power.",

    Bull / Bear case

    analysis pipeline
    — missing data

    In focus — financials by report

    Valuation

    Market price
    ¥35,00
    Market cap
    Enterprise value
    P/E
    Non-GAAP P/E
    EV / Revenue
    EV / Op income
    EV / OCF
    P / B
    P / Tangible book
    Tangible book
    ¥2.79B
    Net cash
    ¥2.81B
    Current ratio
    21.5
    Debt / equity
    0.0
    ROA
    -72.6%
    ROE
    -77.1%
    Cash conversion
    98.0%
    CapEx / revenue
    SBC / revenue
    Dilution ratio
    0.0%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    — missing data

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskLow
    Filing-based flags
    • No immediate filing-based liquidity or dilution flags were detected.

    Benchmarks vs cohort

    ROE-77,1 %Bottom quartile
    D/E0,00Above median
    Cash Conv0,98Above median

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Net Cash
      cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
    • Return On Equity
      net_income / total_equity
    • Debt To Equity
      (short_term_debt + long_term_debt) / total_equity
    • Cash Conversion Ratio
      operating_cash_flow / net_income
    • Return On Assets
      net_income / total_assets
    Source documents
    • 4883.T Market data — financials · 2026-05-26
    • Modalis Therapeutics Corp Market data — analyst estimates · 2026-05-26

    Ownership & reference

    Insider activity

    — missing data

    Short positioning

    — missing data

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    4883.TCanonical
    Tokyo Stock Exchange · JPY

    Intel & risk

    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskLow
    No immediate filing-based liquidity or dilution flags were detected.

    Evidence & claims

    From filings & derived data
    — missing data

    The Thread

    Everything we know, in order
    — missing data
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage